Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-1.29% $0.581
America/New_York / 20 jun 2023 @ 15:11
FUNDAMENTALS | |
---|---|
MarketCap: | 25.48 mill |
EPS: | -1.030 |
P/E: | -0.564 |
Earnings Date: | Aug 08, 2023 |
SharesOutstanding: | 43.83 mill |
Avg Daily Volume: | 0.0525 mill |
RATING 2023-06-20 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.564 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.10x |
Company: PE -0.564 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.565 - 0.597 ( +/- 2.75%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-23 | Klassen Preston | Sell | 842 211 | Common Stock |
2023-03-23 | Klassen Preston | Sell | 842 211 | Stock Option (right to buy) |
2023-01-26 | York Michael | Sell | 107 054 | Common Stock |
2023-01-26 | Klassen Preston | Sell | 380 605 | Common Stock |
2022-12-21 | Leonard Braden Michael | Buy | 120 099 | Common Stock |
INSIDER POWER |
---|
-12.97 |
Last 97 transactions |
Buy: 12 877 287 | Sell: 12 262 808 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.581 (-1.29% ) |
Volume | 0.0839 mill |
Avg. Vol. | 0.0525 mill |
% of Avg. Vol | 159.87 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.